Drugs / alanine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06419686 | Jan → May 2024 | — | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00005889 | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT06881472 Comparator | Jan 2025 → Jan 2026 | type 1 diabetes mellitus | Asger Lund, MD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06881472 ↗ |
| Route | Intravenous | “alanine IV over the last 5 hours” NCT00005889 ↗ |